Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report

Autores
Mastaglia, Silvina Rosana
Año de publicación
2020
Idioma
inglés
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Idiopathic osteoporosis (IOP) affects young, otherwise healthy individuals with intact gonadal function and no secondary cause for bone loss or fragility. IOP may be associated with major osteoporotic fractures such as low-trauma spine or hip. Aim: To evaluate the safety and effectiveness of sequential treatment in premenopausal women diagnosed with IOP. Case Presentation: A33-year-old premenopausal woman was referred by the Gynecology Department to evaluate bone and mineral metabolism.At 28 years of age, the patient had shown a fracture for bone fragility on her right hip. Attaining menarche at age 9, she had regular menstrual cycles (estradiol: 39.3pg/ml and follicle-stimulating hormone: 8.4mIU/l).At the time of consultation, she showed a bone mineral density (BMD, Hologic Equipment, Discovery Wi) in lumbar spine:0.720g/cm2; Z-score: -3.2, and in total left femur: 0.536g/cm2; Z-score: -3.3. No osteoporosis-provoking secondary causes were identified; thus, it was interpreted as IOP. She received sequential therapy (ST) with teriparatide(PTH1-34; Forteo; Eli Lilly&Co., Indianapolis, IN, USA) for two years, and then with densoumab 60mg s.c. (Prolia; Amgen Inc., California, CA, USA) associated with a calcium dietary supply of 1000mg/day and vitamin D3100.000IU/bi-monthly. Results: A 19% increase in LS BMD (least significant change [LSC]: 2.2%) and 16% in FIT (LSC: 3.0%) was observed. Conclusion: The ST was associated with large increase in BMD of LS and FIT in our patient. No adverse effects associated with teriparatide or denosumab were observed. Further clinical studies are necessary to determine the safety and effectiveness of ST in those premenopausal women withIOP. Until then, ST should be used with caution.
Fil: Mastaglia, Silvina Rosana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
The Argentinian Society of Osteology and Mineral Metabolism Annual Meeting
Ciudad de Buenos Aires
Argentina
Asociación Argentina de Osteología y Metabolismo Mineral
Materia
OSTEOPOROSIS IDIOPATICA
TRATAMIENTO SECUENCIAL
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/154115

id CONICETDig_b9ab8dbe1e93596304b58c850a52c8ef
oai_identifier_str oai:ri.conicet.gov.ar:11336/154115
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Sequential treatment for idiopathic osteoporosis in premenopausal women: A case reportMastaglia, Silvina RosanaOSTEOPOROSIS IDIOPATICATRATAMIENTO SECUENCIALhttps://purl.org/becyt/ford/3.2https://purl.org/becyt/ford/3Idiopathic osteoporosis (IOP) affects young, otherwise healthy individuals with intact gonadal function and no secondary cause for bone loss or fragility. IOP may be associated with major osteoporotic fractures such as low-trauma spine or hip. Aim: To evaluate the safety and effectiveness of sequential treatment in premenopausal women diagnosed with IOP. Case Presentation: A33-year-old premenopausal woman was referred by the Gynecology Department to evaluate bone and mineral metabolism.At 28 years of age, the patient had shown a fracture for bone fragility on her right hip. Attaining menarche at age 9, she had regular menstrual cycles (estradiol: 39.3pg/ml and follicle-stimulating hormone: 8.4mIU/l).At the time of consultation, she showed a bone mineral density (BMD, Hologic Equipment, Discovery Wi) in lumbar spine:0.720g/cm2; Z-score: -3.2, and in total left femur: 0.536g/cm2; Z-score: -3.3. No osteoporosis-provoking secondary causes were identified; thus, it was interpreted as IOP. She received sequential therapy (ST) with teriparatide(PTH1-34; Forteo; Eli Lilly&Co., Indianapolis, IN, USA) for two years, and then with densoumab 60mg s.c. (Prolia; Amgen Inc., California, CA, USA) associated with a calcium dietary supply of 1000mg/day and vitamin D3100.000IU/bi-monthly. Results: A 19% increase in LS BMD (least significant change [LSC]: 2.2%) and 16% in FIT (LSC: 3.0%) was observed. Conclusion: The ST was associated with large increase in BMD of LS and FIT in our patient. No adverse effects associated with teriparatide or denosumab were observed. Further clinical studies are necessary to determine the safety and effectiveness of ST in those premenopausal women withIOP. Until then, ST should be used with caution.Fil: Mastaglia, Silvina Rosana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; ArgentinaThe Argentinian Society of Osteology and Mineral Metabolism Annual MeetingCiudad de Buenos AiresArgentinaAsociación Argentina de Osteología y Metabolismo MineralWiley2020info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/154115Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report; The Argentinian Society of Osteology and Mineral Metabolism Annual Meeting; Ciudad de Buenos Aires; Argentina; 2019; 2-22473-4039CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbm4.10340info:eu-repo/semantics/altIdentifier/doi/10.1002/jbm4.10340Nacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:59:45Zoai:ri.conicet.gov.ar:11336/154115instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:59:46.001CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
title Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
spellingShingle Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
Mastaglia, Silvina Rosana
OSTEOPOROSIS IDIOPATICA
TRATAMIENTO SECUENCIAL
title_short Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
title_full Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
title_fullStr Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
title_full_unstemmed Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
title_sort Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report
dc.creator.none.fl_str_mv Mastaglia, Silvina Rosana
author Mastaglia, Silvina Rosana
author_facet Mastaglia, Silvina Rosana
author_role author
dc.subject.none.fl_str_mv OSTEOPOROSIS IDIOPATICA
TRATAMIENTO SECUENCIAL
topic OSTEOPOROSIS IDIOPATICA
TRATAMIENTO SECUENCIAL
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.2
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Idiopathic osteoporosis (IOP) affects young, otherwise healthy individuals with intact gonadal function and no secondary cause for bone loss or fragility. IOP may be associated with major osteoporotic fractures such as low-trauma spine or hip. Aim: To evaluate the safety and effectiveness of sequential treatment in premenopausal women diagnosed with IOP. Case Presentation: A33-year-old premenopausal woman was referred by the Gynecology Department to evaluate bone and mineral metabolism.At 28 years of age, the patient had shown a fracture for bone fragility on her right hip. Attaining menarche at age 9, she had regular menstrual cycles (estradiol: 39.3pg/ml and follicle-stimulating hormone: 8.4mIU/l).At the time of consultation, she showed a bone mineral density (BMD, Hologic Equipment, Discovery Wi) in lumbar spine:0.720g/cm2; Z-score: -3.2, and in total left femur: 0.536g/cm2; Z-score: -3.3. No osteoporosis-provoking secondary causes were identified; thus, it was interpreted as IOP. She received sequential therapy (ST) with teriparatide(PTH1-34; Forteo; Eli Lilly&Co., Indianapolis, IN, USA) for two years, and then with densoumab 60mg s.c. (Prolia; Amgen Inc., California, CA, USA) associated with a calcium dietary supply of 1000mg/day and vitamin D3100.000IU/bi-monthly. Results: A 19% increase in LS BMD (least significant change [LSC]: 2.2%) and 16% in FIT (LSC: 3.0%) was observed. Conclusion: The ST was associated with large increase in BMD of LS and FIT in our patient. No adverse effects associated with teriparatide or denosumab were observed. Further clinical studies are necessary to determine the safety and effectiveness of ST in those premenopausal women withIOP. Until then, ST should be used with caution.
Fil: Mastaglia, Silvina Rosana. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Inmunología, Genética y Metabolismo. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Inmunología, Genética y Metabolismo; Argentina. Universidad de Buenos Aires. Facultad de Medicina. Hospital de Clínicas General San Martín; Argentina
The Argentinian Society of Osteology and Mineral Metabolism Annual Meeting
Ciudad de Buenos Aires
Argentina
Asociación Argentina de Osteología y Metabolismo Mineral
description Idiopathic osteoporosis (IOP) affects young, otherwise healthy individuals with intact gonadal function and no secondary cause for bone loss or fragility. IOP may be associated with major osteoporotic fractures such as low-trauma spine or hip. Aim: To evaluate the safety and effectiveness of sequential treatment in premenopausal women diagnosed with IOP. Case Presentation: A33-year-old premenopausal woman was referred by the Gynecology Department to evaluate bone and mineral metabolism.At 28 years of age, the patient had shown a fracture for bone fragility on her right hip. Attaining menarche at age 9, she had regular menstrual cycles (estradiol: 39.3pg/ml and follicle-stimulating hormone: 8.4mIU/l).At the time of consultation, she showed a bone mineral density (BMD, Hologic Equipment, Discovery Wi) in lumbar spine:0.720g/cm2; Z-score: -3.2, and in total left femur: 0.536g/cm2; Z-score: -3.3. No osteoporosis-provoking secondary causes were identified; thus, it was interpreted as IOP. She received sequential therapy (ST) with teriparatide(PTH1-34; Forteo; Eli Lilly&Co., Indianapolis, IN, USA) for two years, and then with densoumab 60mg s.c. (Prolia; Amgen Inc., California, CA, USA) associated with a calcium dietary supply of 1000mg/day and vitamin D3100.000IU/bi-monthly. Results: A 19% increase in LS BMD (least significant change [LSC]: 2.2%) and 16% in FIT (LSC: 3.0%) was observed. Conclusion: The ST was associated with large increase in BMD of LS and FIT in our patient. No adverse effects associated with teriparatide or denosumab were observed. Further clinical studies are necessary to determine the safety and effectiveness of ST in those premenopausal women withIOP. Until then, ST should be used with caution.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/154115
Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report; The Argentinian Society of Osteology and Mineral Metabolism Annual Meeting; Ciudad de Buenos Aires; Argentina; 2019; 2-2
2473-4039
CONICET Digital
CONICET
url http://hdl.handle.net/11336/154115
identifier_str_mv Sequential treatment for idiopathic osteoporosis in premenopausal women: A case report; The Argentinian Society of Osteology and Mineral Metabolism Annual Meeting; Ciudad de Buenos Aires; Argentina; 2019; 2-2
2473-4039
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://asbmr.onlinelibrary.wiley.com/doi/epdf/10.1002/jbm4.10340
info:eu-repo/semantics/altIdentifier/doi/10.1002/jbm4.10340
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Nacional
dc.publisher.none.fl_str_mv Wiley
publisher.none.fl_str_mv Wiley
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269599571116032
score 13.13397